FID 119515A

Drug Profile

FID 119515A

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alcon
  • Class Eye disorder therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dry eyes

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Dry-eyes in USA (Topical, Drops)
  • 04 Jun 2013 Alcon Research completes a phase I trial in Dry eyes in USA (NCT01833117)
  • 03 May 2013 Phase-I clinical trials in Dry eyes in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top